Prelude Therapeutics Stock Net Income
| PRLD Stock | USD 1.97 0.06 2.96% |
As of the 28th of January, Prelude Therapeutics holds the Semi Deviation of 11.48, risk adjusted performance of 0.0764, and Coefficient Of Variation of 1102.89. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prelude Therapeutics, as well as the relationship between them. Please check Prelude Therapeutics variance, as well as the relationship between the maximum drawdown and semi variance to decide if Prelude Therapeutics is priced some-what accurately, providing market reflects its current price of 1.97 per share. Please also confirm Prelude Therapeutics total risk alpha, which is currently at (0.08) to check out the company can sustain itself at a future point.
Prelude Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 8.5605 | Revenue | Earnings Share (1.47) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -114.5 M | -120.2 M | |
| Net Loss | -103.9 M | -109.1 M | |
| Net Loss | -114.5 M | -120.2 M | |
| Net Loss | (1.51) | (1.59) |
Prelude | Net Income | Build AI portfolio with Prelude Stock |
Latest Prelude Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Prelude Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Prelude Therapeutics financial statement analysis. It represents the amount of money remaining after all of Prelude Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Prelude Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Prelude Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (127.17 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Prelude Net Income Regression Statistics
| Arithmetic Mean | (54,021,952) | |
| Coefficient Of Variation | (91.02) | |
| Mean Deviation | 44,768,179 | |
| Median | (14,680,000) | |
| Standard Deviation | 49,168,214 | |
| Sample Variance | 2417.5T | |
| Range | 112.5M | |
| R-Value | (0.88) | |
| Mean Square Error | 566.2T | |
| R-Squared | 0.78 | |
| Slope | (8,601,580) | |
| Total Sum of Squares | 38680.2T |
Prelude Net Income History
Other Fundumenentals of Prelude Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Prelude Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Prelude Therapeutics is extremely important. It helps to project a fair market value of Prelude Stock properly, considering its historical fundamentals such as Net Income. Since Prelude Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Prelude Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Prelude Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Prelude Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prelude Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prelude Therapeutics.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Prelude Therapeutics on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Prelude Therapeutics or generate 0.0% return on investment in Prelude Therapeutics over 90 days. Prelude Therapeutics is related to or competes with Pyxis Oncology, Orchestra BioMed, Enanta Pharmaceuticals, Caribou Biosciences, Inventiva, Tenaya Therapeutics, and Avalo Therapeutics. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development... More
Prelude Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prelude Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prelude Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 13.63 | |||
| Information Ratio | 0.087 | |||
| Maximum Drawdown | 206.09 | |||
| Value At Risk | (16.17) | |||
| Potential Upside | 16.44 |
Prelude Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prelude Therapeutics' standard deviation. In reality, there are many statistical measures that can use Prelude Therapeutics historical prices to predict the future Prelude Therapeutics' volatility.| Risk Adjusted Performance | 0.0764 | |||
| Jensen Alpha | 2.21 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.1371 | |||
| Treynor Ratio | (0.50) |
Prelude Therapeutics January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0764 | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 9.37 | |||
| Semi Deviation | 11.48 | |||
| Downside Deviation | 13.63 | |||
| Coefficient Of Variation | 1102.89 | |||
| Standard Deviation | 21.49 | |||
| Variance | 461.82 | |||
| Information Ratio | 0.087 | |||
| Jensen Alpha | 2.21 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.1371 | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 206.09 | |||
| Value At Risk | (16.17) | |||
| Potential Upside | 16.44 | |||
| Downside Variance | 185.8 | |||
| Semi Variance | 131.81 | |||
| Expected Short fall | (10.59) | |||
| Skewness | 4.88 | |||
| Kurtosis | 36.16 |
Prelude Therapeutics Backtested Returns
Prelude Therapeutics is abnormally volatile given 3 months investment horizon. Prelude Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.0948, which implies the firm had a 0.0948 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 2.11% are justified by taking the suggested risk. Use Prelude Therapeutics Risk Adjusted Performance of 0.0764, semi deviation of 11.48, and Coefficient Of Variation of 1102.89 to evaluate company specific risk that cannot be diversified away. Prelude Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of -3.87, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Prelude Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Prelude Therapeutics is expected to outperform it. Use Prelude Therapeutics jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to analyze future returns on Prelude Therapeutics.
Auto-correlation | -0.15 |
Insignificant reverse predictability
Prelude Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Prelude Therapeutics time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prelude Therapeutics price movement. The serial correlation of -0.15 indicates that less than 15.0% of current Prelude Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.15 | |
| Spearman Rank Test | -0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Prelude Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Prelude Therapeutics reported net income of (127.17 Million). This is 137.26% lower than that of the Biotechnology sector and 281.56% lower than that of the Health Care industry. The net income for all United States stocks is 122.27% higher than that of the company.
Prelude Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prelude Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics of similar companies.Prelude Therapeutics is currently under evaluation in net income category among its peers.
Prelude Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Prelude Therapeutics from analyzing Prelude Therapeutics' financial statements. These drivers represent accounts that assess Prelude Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Prelude Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 429.8M | 207.5M | 186.9M | 69.8M | 80.3M | 76.3M | |
| Enterprise Value | 399.7M | 178.7M | 178.5M | 75.4M | 86.7M | 82.3M |
Prelude Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Prelude Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Prelude Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Prelude Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Prelude Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Prelude Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Prelude Therapeutics' value.| Shares | Royal Bank Of Canada | 2025-06-30 | 2.8 K |
Prelude Fundamentals
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.14) % | ||||
| Current Valuation | 89.88 M | ||||
| Shares Outstanding | 43.77 M | ||||
| Shares Owned By Insiders | 9.93 % | ||||
| Shares Owned By Institutions | 54.47 % | ||||
| Number Of Shares Shorted | 1.47 M | ||||
| Price To Book | 2.17 X | ||||
| Price To Sales | 12.15 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | 10.5 M | ||||
| EBITDA | (137.94 M) | ||||
| Net Income | (127.17 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 18.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (102.89 M) | ||||
| Short Ratio | 3.09 X | ||||
| Earnings Per Share | (1.47) X | ||||
| Price To Earnings To Growth | (0.09) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 131 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 127.62 M | ||||
| Total Asset | 175.51 M | ||||
| Retained Earnings | (583.56 M) | ||||
| Working Capital | 110.25 M | ||||
| Net Asset | 175.51 M |
About Prelude Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prelude Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prelude Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prelude Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Prelude Therapeutics Piotroski F Score and Prelude Therapeutics Altman Z Score analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.